Exploring the role of CRISPR in cell-based cancer immunotherapy
The use of CRISPR/Cas9 in cancer immunotherapy
DOI:
https://doi.org/10.58445/rars.541Keywords:
Biology, Cancer, immunotherapy, CRISPR/Cas9, medicineAbstract
Cancer immunotherapy, particularly CAR-T cells, has transformed the landscape of cancer treatment, offering a paradigm shift in prognosis. To enhance the efficacy of cancer treatment, recent scientific endeavors have concentrated on harnessing the potential of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology where they use this technology to cancer treatments and cancer immunotherapy including the engineered CAR-T cell. There have been a lot of advances including correcting genetic mutation, curing genetic disorders, etc. this review paper will cover cancer immunotherapy, CAR-T cell therapy and it;s mechanism, successful clinical trials, ongoing clinical trials, the current limitations as well as the future advantages of this technology.
References
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., Wan, X. "Exploiting the CRISPR-Cas9 Gene-Editing System for Human Cancers and Immunotherapy." Cancer Therapy&Immunology,1(1),2021.[Online].Available:https://onlinelibrary.wiley.com/doi/10.1002/cti2.1286 (2021).
"But What is CRISPR-Cas9? An Animated Introduction to Gene Editing." (n.d.). [Video file]. Retrieved from https://www.youtube.com/watch?v=ANehpGhbuF4.
"Understanding CRISPR-Cas9." [Video]. (N.d.). Retrieved from https://www.youtube.com/watch?v=cLMo6DYdJRE.
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., Ji, J. "CRISPR-Cas9 for Cancer Therapy: Opportunities and Challenges." Journal of Cancer Therapy, 447, 48-55. [Online]. Available: https://dpl6hyzg28thp.cloudfront.net/media/CRISPR-Cas9_for_cancer_therapy_Opportunities_and_challenges.pdf (2020]).
National Cancer Institute (NCI). "CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers." https://www.cancer.gov/about-cancer/treatment/research/car-t-cells. (2022).
Malech, H. L. "Treatment by CRISPR-Cas9 Gene Editing — A Proof of Principle." The New England Journal of Medicine, 2021. [Online]. Available: https://www.nejm.org/doi/10.1056/NEJMe2034624?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed (2021).
Roberts, R. "CRISPR in Cancer Therapeutics: CAR-T, NK, TCR and Beyond." [Online]. Available at: https://www.synthego.com/blog/crispr-cancer-therapy#the-current-landscape-of-crispr-cancer-therapeutics. (2022, ARCH).
Ghaffari, S., Khalili, N., Rezaei, N. "CRISPR/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy." Journal of Experimental & Clinical Cancer Research, 40(269), August 2021. [Online]. Available: https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02076-5#Sec12 (2021).
"Immunology: T Cell Receptor Structure and Function." (n.d.). [Video]. YouTube. Retrieved from https://www.youtube.com/watch?v=uq9p26JAnCs.
Wang, L., Chen, Y., Liu, X., Li, Z., Dai, X. "The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems." Cancer Research Journal, 11, 704999. (January 2022). [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801488/ (2022).
Khalaf, K., Janowicz, K., Dyszkiewicz-Konwińska, M., Hutchings, G., Dompe, C., Moncrieff, L., Jankowski, M., et al. "CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials." Genes, 11(8), 921. (2020). [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463827/ (2020).
Wang, V., Gauthier, M., Decot, V., Reppel, L., Bensoussan, D. "Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input." Journal of Cellular Immunotherapy, 3(1), February 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954171/ (2023).
"Yescarta™ (axicabtagene ciloleucel)." Roswell Park Comprehensive Cancer Center. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/yescarta. (2022)
"Kymriah™ (tisagenlecleucel)." Roswell Park Comprehensive Cancer Center..https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/kymriah.(2022)
"Tecartus™ (Brexucabtagene Autoleucel)." Roswell Park Comprehensive Cancer Center. Accessed August 31, 2023. [Online]. Available: https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/tecartus. (2022)
"Abecma™ (idecabtagene vicleucel)." Roswell Park Comprehensive Cancer Center.. https://www.roswellpark.org/cancer-care/treatments/immunotherapy/what-immunotherapy/abecma. (2023)
Johnson&Johnson. "U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma." (2022). [Online].Available:https://www.jnj.com/u-s-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-a-bcma-directed-car-t-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma (2022).
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., Ahn, B. C. "CAR T-Cell-Based Gene Therapy for Cancers: New Perspectives, Challenges, and Clinical Developments." Cancer Gene Therapy, 4(2), 2022. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355792/ (2022).
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., Ahn, B. C. "CAR T-Cell-Based Gene Therapy for Cancers: New Perspectives, Challenges, and Clinical Developments." Cancer Gene Therapy, 5(3), July 2022. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355792/ (2022).
AYANOĞLU, F. B., ELÇİN, A. E., ELÇİN, Y. M. "Bioethical Issues in Genome Editing by CRISPR-Cas9Technology."JournalofBioethics,[Online].Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129066/ (2021).
National Institutes of Health (NIH). "Principles for Governance of Human Genome Editing." [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK447266/. (2020)
Lino, C. A., Harper, J. C., Carney, J. P., Timlin, J. A. "Delivering CRISPR: A Review of the Challenges and Approaches." Journal of Controlled Release, 279, 184-192. (2018). [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058482/ (2018).
Yadollahpour, A. "CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research." FrontiersinMedicine,2021.[Online].Available:https://www.frontiersin.org/articles/10.3389/fmed.2021.649896/full (2021).
"How CRISPR Is Changing Cancer Research and Treatment." (2020). National Cancer Institute. [Online]. Available: https://www.cancer.gov/news-events/cancer-currents-blog/2020/crispr-cancer-research-treatment (2020).
Additional Files
Posted
Categories
License
Copyright (c) 2023 Meha Farrokhi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.